GlassScriptPhysician profile
Ryan Skowronek
NPI 1306411202
$1,541.75
in general payments reported to CMS, 2019-2025
15 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $228 · 2023: $586 · 2024: $588 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,313.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $413.25 | 2023-2024 | Briviact, Rystiggo |
| Boston Scientific Corporation | $199.93 | 2023-2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $179.67 | 2023-2025 | Botox, Duopa |
| Depuy Synthes Sales INC. | $120.79 | 2024 | Cerebase |
| Acadia Pharmaceuticals INC | $119.79 | 2023-2024 | Nuplazid |
| Neurocrine Biosciences, INC. | $118.17 | 2025 | |
| Sk Life Science, INC. | $85.09 | 2022 | |
| Medtronic, INC. | $78.58 | 2022 | |
| Jazz Pharmaceuticals INC. | $63.14 | 2023 | |
| Allergan, INC. | $47.88 | 2022 | |
| Argenx US, INC. | $47.19 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Genentech USA, INC. | $20.17 | 2024 | Enspryng, Ocrevus |
| Celgene Corporation | $17.68 | 2023 | Zeposia |
| Cala Health, INC. | $16.50 | 2022 | |
| Neurelis, INC. | $13.92 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Skowronek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.